AMY K. TAYLOR, PH.D.; SIMEON I. TAYLOR, M.D., PH.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: This letter is a comment on the economic analysis of the therapy of hyperuricemia as outlined by Liang and Fries (Ann Intern Med 88:666-670, 1978). They assume that the cost of therapy with allopurinol is $110 per year. From that they estimate a lifetime cost of $20 000 based on an interest rate of 7%. However, this calculation is misleading because it does not take time and the interest rate into account properly.
A more useful approach is to calculate the present value (see Reference 1) of the total cost of a lifetime of allopurinol therapy. In
TAYLOR AK, TAYLOR SI. Asymptomatic Hyperuricemia. Ann Intern Med. ;89:426–427. doi: 10.7326/0003-4819-89-3-426_2
Download citation file:
Published: Ann Intern Med. 1978;89(3):426-427.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use